Articles dans des revues avec comité de lecture (165)
  1. 114. Lelubre, C., Zouaoui Boudjeltia, K., Van Antwerpen, P., Vanhaeverbeek, M., & Roumeguere, T. (2010). Phosphodiesterase Inhibitors in the Treatment of Inflammatory Disorders: A Narrative Review. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 9(2), 1-15.
  2. 115. Franck, T., Kohnen, S. S., Zouaoui Boudjeltia, K., Van Antwerpen, P., Bosseloir, A., Niesten, A., Gach, O., Nys, M., Deby-Dupont, G., & Serteyn, D. (2009). A new easy method for specific measurement of active myeloperoxidase in human biological fluids and tissue extracts. Talanta, 80(2), 723-729. doi:10.1016/j.talanta.2009.07.052
  3. 116. Roumeguere, T., Van Antwerpen, P., Zouaoui Boudjeltia, K., Vanhaeverbeek, M., & Wespes, E. (2009). Maladies cardiovasculaires, dysfonction érectile et myéloperoxydase. Angéiologie, 61(3), 88-92.
  4. 117. Aminian, A., Zouaoui Boudjeltia, K., Babar, S., Van Antwerpen, P., Lefebvre, P., Crasset, V., Leone, A., Ducobu, J., Friart, A., & Vanhaeverbeek, M. (2009). Coronary stenting is associated with an acute increase in plasma myeloperoxidase in stable angina patients but not in patients with acute myocardial infarction. European journal of internal medicine, 20(5), 527-532. doi:10.1016/j.ejim.2009.05.008
  5. 118. Roumeguere, T., Zouaoui Boudjeltia, K., Hauzeur, C., Schulman, C., Vanhaeverbeek, M., & Wespes, E. (2009). Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? BJU international, 104(4), 511-517. doi:10.1111/j.1464-410X.2009.08418.x
  6. 119. Mendes Dos Santos, S., Candi, A., Vansteenbrugge, M., Pignon, M.-R., Bult, H., Zouaoui Boudjeltia, K., Munaut, C., & Raes, M. (2009). Microarray analyses of the effects of NF-kappaB or PI3K pathway inhibitors on the LPS-induced gene expression profile in RAW264.7 cells: synergistic effects of rapamycin on LPS-induced MMP9-overexpression. Cellular signalling, 21(7), 1109-1122. doi:10.1016/j.cellsig.2009.02.025
  7. 120. Kerkhofs, M., Faraut, B., Zouaoui Boudjeltia, K., & Vanhaeverbeek, M. (2009). Restriction de sommeil et risque cardiovasculaire. Medecine du Sommeil, 6(3), 95-98. doi:10.1016/j.msom.2009.10.002
  8. 121. Prévot, P.-P., Beschin, A., Lins, L., Beaufays, J., Grosjean, A., Bruys, L., Adam, B., Brossard, M., Brasseur, R., Zouaoui Boudjeltia, K., Vanhamme, L., & Godfroid, E. (2009). Exosites mediate the anti-inflammatory effects of a multifunctional serpin from the saliva of the tick Ixodes ricinus. The FEBS journal, 276(12), 3235-3246. doi:10.1111/j.1742-4658.2009.07038.x
  9. 122. Zouaoui Boudjeltia, K., Ollieuz, S., Piagnerelli, M., Biston, P., Cauchie, P., Vincent, J. L., Brohée, D., & Vanhaeverbeek, M. (2009). Plasma fibrinolysis is related to the degree of organ dysfunction but not to the concentration of von Willebrand factor in critically ill patients. Thrombosis Journal, 7, 10. doi:10.1186/1477-9560-7-10
  10. 123. Piagnerelli, M., Zouaoui Boudjeltia, K., Rapotec, A., Richard, T., Brohée, D., Babar, S., Bouckaert, V., Simon, A.-C., Toko, J.-P., Walravens, T., Vincent, J. L., & Vanhaeverbeek, M. (2009). Neuraminidase alters red blood cells in sepsis. Critical care medicine, 37(4), 1244-1250. doi:10.1097/CCM.0b013e31819cebbe
  11. 124. Roumeguere, T., Zouaoui Boudjeltia, K., & Vanhaeverbeek, M. (2009). Effect of LDL modified by myeloperoxidase-H2O2-Cl(-) system on intracellular cyclic guanosine monophosphate level of endothelial cells: a link to erectile dysfunction? European urology, 55(3), 754-755. doi:10.1016/j.eururo.2008.09.038
  12. 125. Roumeguere, T., Zouaoui Boudjeltia, K., Hauzeur, C., Ramal, A., Schulman, C., Vanhaeverbeek, M., Ducobu, J., & Wespes, E. (2008). Diminution du rapport ApoB/ApoA-1 et amélioration du risque cardiovasculaire : effet pleïotropique du tadalafil ? Étude préliminaire sur volontaires sains. Progrès en urologie, 18(13), 1087-1091. doi:10.1016/j.purol.2008.09.057
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Suivant >>